University of Leuven, Translational Research Center for Gastrointestinal Disorders, Herestraat 49, B-3000 Leuven, Belgium.
Expert Opin Drug Metab Toxicol. 2012 Oct;8(10):1327-35. doi: 10.1517/17425255.2012.719497.
Prucalopride is the first member of a novel class of 5-HT(4) receptor agonist which has been extensively evaluated for the treatment of chronic constipation. Predominantly, prucalopride is currently used to treat patients that show an insufficient response to laxatives as an alternative form of therapy.
The following article provides the reader with a systematic review of the literature on prucalopride. Specifically, the article reviews the currently literature on the pharmacokinetics and the pharmacodynamics of the drugs as well as reviewing literature on its efficacy. Furthermore, the authors also highlight the safety and tolerability of the drug that have been demonstrated in its clinical development.
Prucalopride is an important addition to the therapeutic abilities for treating chronic constipation, especially in females poorly responding to laxatives. The safety profile of the drug, to date, is favorable. There is also the possibility that prucalopride might be of benefit to other disorders of gastrointestinal motility with a number of studies currently in progress, which are evaluating alternative applications.
普芦卡必利是一种新型 5-HT（4）受体激动剂，已广泛用于治疗慢性便秘。普芦卡必利主要用于治疗对泻药反应不足的患者，作为替代治疗形式。
本文为读者提供了普芦卡必利文献的系统评价。具体而言，本文综述了该药物的药代动力学和药效学的现有文献，以及其疗效的文献。此外，作者还强调了该药物在临床开发中表现出的安全性和耐受性。
普芦卡必利是治疗慢性便秘的一种重要治疗方法，尤其是对泻药反应不佳的女性。迄今为止，该药物的安全性良好。也有可能普芦卡必利对其他胃肠道动力障碍疾病也有帮助，目前有许多正在进行的研究，评估其替代应用。
